Cigna vs Labcorp
Cigna is the larger business, with $274.90bn of revenue in fiscal 2025 against $13.95bn for Labcorp (19.7 times as much). Cigna grew faster (11.2% against 7.2%). Labcorp kept more of each dollar of sales as profit: a net margin of 6.3% against 2.2%. Labcorp carries less debt relative to equity (64.8% against 75.4%).
| Latest fiscal year | CignaCI, 2025 | LabcorpLH, 2025 |
|---|---|---|
| Revenue | $274.90bn | $13.95bn |
| Revenue growth | 11.2% | 7.2% |
| Net income | $5.96bn | $877m |
| Operating margin | 3.3% | 9.9% |
| Net margin | 2.2% | 6.3% |
| Return on equity | 14.4% | 10.5% |
| Free cash flow | $9.60bn | $1.21bn |
| Cash | $7.68bn | $532m |
| Total debt | $31.46bn | $5.58bn |
| Debt to equity | 75.4% | 64.8% |
| Dividend per share | $6.04 | $2.88 |
| Dividend yield | 2.1% | 0.8% |
| Share buybacks | $3.62bn | $450m |
| Employees | 67,700 | — |
| Market value | $77.70bn | $28.61bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 57 (Moderate) | 61 (Moderate) |
| Insider trades, 12 months | 1 buys, 19 sales | 0 buys, 20 sales |